$951.19
-8.22-0.86%
al cierre: Nov 11, 4:00 PM EST
$953.91
-5.50-0.57%
Premercado: 5:23 AM EST
Regeneron Pharmaceuticals rose 36.9% from $694.99 to $951.19, ahead of the S&P 500's +12.7%. Its worst day was May 18 (−9.8%), and its low came Jun 1 at $600.66.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Morgan Stanley moved Regeneron Pharmaceuticals from Overweight to Equal-Weight with a $767.00 price target; shares fell 7.2%.
−7.2% · S&P 500 +0.1%
Story events cover the past 12 months · Times ET
EPS of $11.44 beat the $9.69 estimate on $3.9B revenue (est. $3.8B).
−1.1% · S&P 500 −0.3%
EPS of $9.47 beat the $8.38 estimate on $3.6B revenue (est. $3.5B).
−6.2% · S&P 500 0.0%
The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)A numeric improvement of 5.1 months in median PFS was observed for the high-dose fianlimab
−9.8%, the year's worst day, on 3M shares, the year's heaviest volume · S&P 500 −0.1%
Regeneron Pharmaceuticals closed at its lowest level of the year, 13.6% below where the year started.
−2.3% · S&P 500 +0.3%
EPS of $14.29 beat the $10.34 estimate on $4.3B revenue (est. $3.8B).
+6.2% · S&P 500 +1.7%
EPS of $20.07 beat the $15.75 estimate on $5.1B revenue (est. $4.6B).
+13.3%, the year's best day · S&P 500 −1.8%
Where it ended: a close of $951.19 on Nov 12, 2026. Up next: Q4 2026 earnings on Jan 29, 2027 (EPS est. $24.57, revenue est. $5.8B).
As of the Nov 12, 2026 close
Replay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for REGN and SPY from Benzinga historical bars. Not investment advice.